Get the Stockscreener App
5.99
1.56%
-0.095
Pre-market:
6.00
0.010
+0.17%
Rxsight Inc stock is traded at $5.99, with a volume of 621.75K.
It is down -1.56% in the last 24 hours and down -17.38% over the past month.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
See More
Previous Close:
$6.085
Open:
$6.15
24h Volume:
621.75K
Relative Volume:
0.86
Market Cap:
$247.97M
Revenue:
$134.48M
Net Income/Loss:
$-38.94M
P/E Ratio:
-6.2828
EPS:
-0.9534
Net Cash Flow:
$-19.34M
1W Performance:
+0.67%
1M Performance:
-17.38%
6M Performance:
-48.00%
1Y Performance:
-61.80%
1-Day Range:
$5.92
$6.15
1-Week Range:
$5.79
$6.53
52-Week Range:
$5.30
$16.48
Rxsight Inc Stock (RXST) Company Profile
Name
Rxsight Inc
Sector
Industry
Phone
949-521-7822
Address
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
5.99 | 251.90M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
86.67 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
313.00 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.60 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.64 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.54 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | William Blair | Mkt Perform |
| Jul-15-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-25 | Downgrade | Jefferies | Buy → Hold |
| Jul-09-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-09-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-09-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-19-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-15-25 | Initiated | Piper Sandler | Neutral |
| Apr-09-25 | Downgrade | UBS | Buy → Neutral |
| Apr-04-25 | Downgrade | JP Morgan | Overweight → Underweight |
| Apr-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-20-24 | Downgrade | Stifel | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | UBS | Buy |
| Oct-29-24 | Initiated | Jefferies | Buy |
| Aug-20-24 | Reiterated | Needham | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| May-07-24 | Reiterated | BTIG Research | Buy |
| Dec-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Initiated | Morgan Stanley | Overweight |
| Apr-13-23 | Initiated | Oppenheimer | Outperform |
| Dec-12-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-08-22 | Initiated | Needham | Buy |
View All
Rxsight Inc Stock (RXST) Latest News
Avoiding Lag: Real-Time Signals in (RXST) Movement - Stock Traders Daily
RxSight Inc. Q1 2026 Earnings: EPS Misses Estimates Amid Operational HeadwindsGuidance vs Actual - Newser
Midday Stock Roundup: Glaukos Corp. Shares Drop 11% - Orange County Business Journal
RxSight to present at Stifel 2026 Virtual Ophthalmology Forum on May 26 - Pluang
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum - The Manila Times
RxSight management to appear at Stifel 2026 virtual eye forum May 26 - Stock Titan
RxSight stock (US78419L1008): Q1 revenue dip and share slide put growth story to the test - AD HOC NEWS
Tarsus, RxSight Fall Despite Growth Signals - Orange County Business Journal
RxSight stock (US78419L1008): FDA-linked growth and execution stay in focus - AD HOC NEWS
RxSight stock (US78419L1008): FDA-backed growth story stays in focus - AD HOC NEWS
Number of shareholders of RxSight, Inc. – NASDAQ:RXST - TradingView
Discipline and Rules-Based Execution in RXST Response - Stock Traders Daily
RxSight Earnings Call Balances Growth With Headwinds - TipRanks
TradingKey - TradingKey
BofA Securities Maintains RxSight(RXST.US) With Sell Rating - Moomoo
RXST: Stable Q1 results and ongoing commercial initiatives support sequential growth and global expansion - TradingView
Artisan Partners reports 5.0% stake in RxSight (NASDAQ: RXST) - Stock Titan
Midday Stock Roundup: Skyworks Solutions Falls - Orange County Business Journal
RxSight (RXST) Q1 2026 Earnings Transcript - AOL.com
RxSight, Inc. (NASDAQ:RXST) Q1 2026 Earnings Call Transcript - Insider Monkey
RxSight (RXST) Gets a Hold from Stifel Nicolaus - The Globe and Mail
William Blair Maintains RxSight(RXST.US) With Hold Rating - Moomoo
RxSight (RXST) Loss Widening To US$46.6 Million Tests Bullish Growth Narratives - Sahm
RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook - VisionMonday.com
Piper Sandler Maintains RxSight(RXST.US) With Hold Rating, Maintains Target Price $10 - Moomoo
RxSight, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Needham Maintains RxSight(RXST.US) With Buy Rating, Cuts Target Price to $11 - Moomoo
RxSight Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: RxSight beats Q1 2026 forecasts, stock dips By Investing.com - Investing.com Australia
RXST: Q1 revenue fell 18% year-over-year, but LAL volumes stabilized and gross margin improved - TradingView
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Rxsight Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: RxSight beats Q1 2026 forecasts, stock dips - Investing.com
RxSight (NASDAQ:RXST) Q1 2026 Results: Revenue Beats but Loss Widens Amid Cautious Market Reaction - ChartMill
RxSight, Inc. (RXST) Tops Q1 EPS by 12c - StreetInsider
RxSight (RXST) Q1 2026 revenue drops 18.5% as net loss nearly doubles - Stock Titan
Eye-lens maker RxSight says sales slowed, but kept 2026 target - Stock Titan
RxSight, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
RxSight (NASDAQ: RXST) posts wider Q1 loss but keeps 2026 sales outlook - Stock Titan
How many employees work at RxSight? - Revelio Labs
symbol__ Stock Quote Price and Forecast - CNN
Rxsight Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Behavioral Patterns of RXST and Institutional Flows - Stock Traders Daily
How The RxSight (RXST) Narrative Is Shifting After 2026 Guidance And Target Resets - Yahoo Finance
Earnings Preview: RxSight to Report Financial Results Post-market on May 06 - Moomoo
RxSight, Inc. to Present at the Bank of America Healthcare Conference - Bluefield Daily Telegraph
Investors can watch RxSight's Bank of America fireside chat May 13 - Stock Titan
Needham Maintains RxSight (RXST) Buy Recommendation - MSN
RxSight (RXST) to Release Earnings on Wednesday - MarketBeat
RxSight (NASDAQ: RXST) sets 2026 virtual meeting on directors, pay and auditor - Stock Titan
[ARS] RxSight, Inc. SEC Filing - Stock Titan
Rxsight Inc Stock (RXST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
2.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):